Search
Glyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigationalGlyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. … [L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].
Categories: Drugs Used in DiabetesSynonyms: 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamideTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalAlterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalFood and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538]. … Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533
Categories: Drugs Used in Hereditary AngioedemaSynonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideAjmaline
go.drugbank.com/drugs/DB01426ApprovedWithdrawnAn alkaloid found in the root of Rauwolfia serpentina, among other plant sources. … The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IaEtranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … [L46287] It was fully approved by the EMA in May 2023.[L46596]
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Glucagon-like peptide II (2-glycine) (human)Disopyramide
go.drugbank.com/drugs/DB00280ApprovedInvestigationalIt also possesses some anticholinergic and local anesthetic properties. … A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IaAmiloxate
go.drugbank.com/drugs/DB11207ApprovedAmiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].
Mixtures: The History of Whoo Jin Hae Yoon SunNuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … a productive infection in humans.